Illumina, Inc. (0J8Z.L)
USD 71.29
(-2.45%)
USD 71.29
(-2.45%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 4.5 Billion USD | -1.75% |
| 2022 | 4.58 Billion USD | 1.28% |
| 2021 | 4.52 Billion USD | 39.73% |
| 2020 | 3.23 Billion USD | -8.58% |
| 2019 | 3.54 Billion USD | 6.3% |
| 2018 | 3.33 Billion USD | 21.11% |
| 2017 | 2.75 Billion USD | 14.74% |
| 2016 | 2.39 Billion USD | 8.05% |
| 2015 | 2.21 Billion USD | 19.25% |
| 2014 | 1.86 Billion USD | 30.97% |
| 2013 | 1.42 Billion USD | 23.74% |
| 2012 | 1.14 Billion USD | 8.81% |
| 2011 | 1.05 Billion USD | 16.93% |
| 2010 | 902.74 Million USD | 35.48% |
| 2009 | 666.32 Million USD | 16.24% |
| 2008 | 573.22 Million USD | 56.28% |
| 2007 | 366.79 Million USD | 98.71% |
| 2006 | 184.58 Million USD | 151.13% |
| 2005 | 73.5 Million USD | 45.31% |
| 2004 | 50.58 Million USD | 80.43% |
| 2003 | 28.03 Million USD | 179.23% |
| 2002 | 10.04 Million USD | 303.86% |
| 2001 | 2.48 Million USD | 89.9% |
| 2000 | 1.3 Million USD | 176.17% |
| 1999 | 474.02 Thousand USD | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q2 | 1.11 Billion USD | 3.35% |
| 2024 Q3 | 1.08 Billion USD | -2.88% |
| 2024 Q1 | 1.07 Billion USD | -4.1% |
| 2023 Q4 | 1.12 Billion USD | 0.27% |
| 2023 FY | 4.5 Billion USD | -1.75% |
| 2023 Q1 | 1.08 Billion USD | 0.37% |
| 2023 Q2 | 1.17 Billion USD | 8.19% |
| 2023 Q3 | 1.11 Billion USD | -4.85% |
| 2022 Q4 | 1.08 Billion USD | -2.87% |
| 2022 FY | 4.58 Billion USD | 1.28% |
| 2022 Q1 | 1.22 Billion USD | 2.09% |
| 2022 Q2 | 1.16 Billion USD | -4.99% |
| 2022 Q3 | 1.11 Billion USD | -4.04% |
| 2021 Q3 | 1.1 Billion USD | -1.6% |
| 2021 Q4 | 1.19 Billion USD | 8.12% |
| 2021 FY | 4.52 Billion USD | 39.73% |
| 2021 Q1 | 1.09 Billion USD | 14.69% |
| 2021 Q2 | 1.12 Billion USD | 3.02% |
| 2020 Q3 | 794 Million USD | 25.43% |
| 2020 Q4 | 953 Million USD | 20.03% |
| 2020 Q1 | 859 Million USD | -9.86% |
| 2020 Q2 | 633 Million USD | -26.31% |
| 2020 FY | 3.23 Billion USD | -8.58% |
| 2019 Q4 | 953 Million USD | 5.07% |
| 2019 FY | 3.54 Billion USD | 6.3% |
| 2019 Q3 | 907 Million USD | 8.23% |
| 2019 Q2 | 838 Million USD | -0.95% |
| 2019 Q1 | 846 Million USD | -2.42% |
| 2018 Q4 | 867 Million USD | 1.64% |
| 2018 Q3 | 853 Million USD | 2.77% |
| 2018 FY | 3.33 Billion USD | 21.11% |
| 2018 Q1 | 782 Million USD | 0.51% |
| 2018 Q2 | 830 Million USD | 6.14% |
| 2017 Q1 | 598 Million USD | -3.45% |
| 2017 Q3 | 714 Million USD | 7.85% |
| 2017 Q4 | 778 Million USD | 8.96% |
| 2017 FY | 2.75 Billion USD | 14.74% |
| 2017 Q2 | 662 Million USD | 10.7% |
| 2016 Q1 | 571.76 Million USD | -3.34% |
| 2016 Q2 | 600.12 Million USD | 4.96% |
| 2016 FY | 2.39 Billion USD | 8.05% |
| 2016 Q3 | 607.13 Million USD | 1.17% |
| 2016 Q4 | 619.34 Million USD | 2.01% |
| 2015 FY | 2.21 Billion USD | 19.25% |
| 2015 Q3 | 550.27 Million USD | 2.02% |
| 2015 Q4 | 591.54 Million USD | 7.5% |
| 2015 Q1 | 538.56 Million USD | 5.11% |
| 2015 Q2 | 539.37 Million USD | 0.15% |
| 2014 Q1 | 420.78 Million USD | 8.64% |
| 2014 Q2 | 447.56 Million USD | 6.37% |
| 2014 Q3 | 480.63 Million USD | 7.39% |
| 2014 FY | 1.86 Billion USD | 30.97% |
| 2014 Q4 | 512.37 Million USD | 6.61% |
| 2013 Q1 | 330.95 Million USD | 7.01% |
| 2013 Q3 | 356.8 Million USD | 3.09% |
| 2013 Q4 | 387.32 Million USD | 8.56% |
| 2013 FY | 1.42 Billion USD | 23.74% |
| 2013 Q2 | 346.09 Million USD | 4.57% |
| 2012 FY | 1.14 Billion USD | 8.81% |
| 2012 Q4 | 309.26 Million USD | 8.18% |
| 2012 Q1 | 272.77 Million USD | 9.08% |
| 2012 Q3 | 285.87 Million USD | 1.88% |
| 2012 Q2 | 280.6 Million USD | 2.87% |
| 2011 Q2 | 287.45 Million USD | 1.75% |
| 2011 Q4 | 250.07 Million USD | 6.19% |
| 2011 FY | 1.05 Billion USD | 16.93% |
| 2011 Q3 | 235.49 Million USD | -18.07% |
| 2011 Q1 | 282.51 Million USD | 8.12% |
| 2010 Q2 | 212 Million USD | 10.34% |
| 2010 Q3 | 237.3 Million USD | 11.94% |
| 2010 Q4 | 261.29 Million USD | 10.11% |
| 2010 FY | 902.74 Million USD | 35.48% |
| 2010 Q1 | 192.13 Million USD | 6.41% |
| 2009 Q4 | 180.56 Million USD | 14.02% |
| 2009 Q2 | 161.64 Million USD | -2.48% |
| 2009 Q1 | 165.75 Million USD | 3.0% |
| 2009 FY | 666.32 Million USD | 16.24% |
| 2009 Q3 | 158.36 Million USD | -2.03% |
| 2008 Q4 | 160.92 Million USD | 7.1% |
| 2008 Q2 | 140.17 Million USD | 15.03% |
| 2008 Q3 | 150.26 Million USD | 7.19% |
| 2008 FY | 573.22 Million USD | 56.28% |
| 2008 Q1 | 121.86 Million USD | 8.22% |
| 2007 Q4 | 112.6 Million USD | 15.48% |
| 2007 Q3 | 97.51 Million USD | 15.35% |
| 2007 Q2 | 84.53 Million USD | 17.17% |
| 2007 FY | 366.79 Million USD | 98.71% |
| 2007 Q1 | 72.15 Million USD | 19.38% |
| 2006 Q3 | 53.47 Million USD | 28.61% |
| 2006 FY | 184.58 Million USD | 151.13% |
| 2006 Q4 | 60.43 Million USD | 13.02% |
| 2006 Q2 | 41.57 Million USD | 42.87% |
| 2006 Q1 | 29.1 Million USD | 26.46% |
| 2005 Q1 | 15.14 Million USD | 2.47% |
| 2005 Q2 | 15.82 Million USD | 4.46% |
| 2005 Q3 | 19.51 Million USD | 23.33% |
| 2005 Q4 | 23.01 Million USD | 17.92% |
| 2005 FY | 73.5 Million USD | 45.31% |
| 2004 Q2 | 11.48 Million USD | 6.32% |
| 2004 Q4 | 14.78 Million USD | 9.41% |
| 2004 Q3 | 13.51 Million USD | 17.64% |
| 2004 Q1 | 10.8 Million USD | 0.58% |
| 2004 FY | 50.58 Million USD | 80.43% |
| 2003 Q3 | 8.24 Million USD | 72.97% |
| 2003 Q4 | 10.74 Million USD | 30.21% |
| 2003 FY | 28.03 Million USD | 179.23% |
| 2003 Q1 | 4.27 Million USD | 10.04% |
| 2003 Q2 | 4.76 Million USD | 11.53% |
| 2002 Q3 | 2.98 Million USD | 57.11% |
| 2002 FY | 10.04 Million USD | 303.86% |
| 2002 Q2 | 1.9 Million USD | 49.72% |
| 2002 Q1 | 1.26 Million USD | 66.73% |
| 2002 Q4 | 3.88 Million USD | 30.18% |
| 2001 Q1 | 563.69 Thousand USD | 16.31% |
| 2001 FY | 2.48 Million USD | 89.9% |
| 2001 Q4 | 761.11 Thousand USD | 10.09% |
| 2001 Q3 | 691.35 Thousand USD | 47.15% |
| 2001 Q2 | 469.84 Thousand USD | -16.65% |
| 2000 FY | 1.3 Million USD | 176.17% |
| 2000 Q3 | 662.58 Thousand USD | 742.43% |
| 2000 Q1 | 83.2 Thousand USD | 0.0% |
| 2000 Q2 | 78.65 Thousand USD | -5.47% |
| 2000 Q4 | 484.66 Thousand USD | -26.85% |
| 1999 FY | 474.02 Thousand USD | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| uniQure N.V. | 15.84 Million USD | -28328.959% |
| Abeona Therapeutics Inc. | 3.5 Million USD | -128585.714% |
| Aclaris Therapeutics, Inc. | 31.24 Million USD | -14313.261% |
| Agilent Technologies, Inc. | 6.83 Billion USD | 34.085% |
| Agios Pharmaceuticals, Inc. | 26.82 Million USD | -16691.559% |
| Alnylam Pharmaceuticals, Inc. | 1.82 Billion USD | -146.35% |
| Amicus Therapeutics, Inc. | 399.35 Million USD | -1027.816% |
| Anavex Life Sciences Corp. | - USD | -Infinity% |
| Atara Biotherapeutics, Inc. | 8.57 Million USD | -52437.035% |
| Axsome Therapeutics, Inc. | 270.6 Million USD | -1564.449% |
| BioMarin Pharmaceutical Inc. | 2.41 Billion USD | -86.175% |
| bluebird bio, Inc. | 29.49 Million USD | -15169.349% |
| Blueprint Medicines Corporation | 249.38 Million USD | -1706.079% |
| Cara Therapeutics, Inc. | 20.96 Million USD | -21380.351% |
| Imunon, Inc. | - USD | -Infinity% |
| Adicet Bio, Inc. | - USD | -Infinity% |
| Corcept Therapeutics Incorporated | 482.37 Million USD | -833.713% |
| Dynavax Technologies Corporation | 232.28 Million USD | -1839.006% |
| Editas Medicine, Inc. | 78.12 Million USD | -5665.268% |
| Emergent BioSolutions Inc. | 1.04 Billion USD | -329.239% |
| Esperion Therapeutics, Inc. | 116.33 Million USD | -3771.611% |
| Exelixis, Inc. | 1.83 Billion USD | -146.092% |
| FibroGen, Inc. | 147.75 Million USD | -2948.351% |
| Geron Corporation | 237 Thousand USD | -1900321.941% |
| Halozyme Therapeutics, Inc. | 829.25 Million USD | -443.139% |
| Heron Therapeutics, Inc. | 127.04 Million USD | -3445.228% |
| Incyte Corporation | 3.69 Billion USD | -21.873% |
| Insmed Incorporated | 305.2 Million USD | -1375.715% |
| Intellia Therapeutics, Inc. | 36.27 Million USD | -12316.265% |
| Ionis Pharmaceuticals, Inc. | 787.64 Million USD | -471.83% |
| Iovance Biotherapeutics, Inc. | 1.18 Million USD | -378705.719% |
| IQVIA Holdings Inc. | 14.98 Billion USD | 69.941% |
| Kala Pharmaceuticals, Inc. | - USD | -Infinity% |
| Mettler-Toledo International Inc. | 3.78 Billion USD | -18.892% |
| Evolus, Inc. | 202.08 Million USD | -2128.765% |
| Myriad Genetics, Inc. | 678.4 Million USD | -563.915% |
| Neurocrine Biosciences, Inc. | 1.88 Billion USD | -138.673% |
| OPKO Health, Inc. | 863.49 Million USD | -421.601% |
| Sarepta Therapeutics, Inc. | 1.24 Billion USD | -262.251% |
| Supernus Pharmaceuticals, Inc. | 607.52 Million USD | -641.374% |
| Verastem, Inc. | - USD | -Infinity% |
| Walgreens Boots Alliance, Inc. | 147.65 Billion USD | 96.95% |
| Waters Corporation | 2.95 Billion USD | -52.347% |
| Zoetis Inc. | 8.54 Billion USD | 47.285% |
| Vertex Pharmaceuticals Incorporated | 9.86 Billion USD | 54.363% |
| Thermo Fisher Scientific Inc. | 42.85 Billion USD | 89.491% |
| Biogen Inc. | 9.83 Billion USD | 54.207% |
| Sangamo Therapeutics, Inc. | 176.23 Million USD | -2455.722% |
| Regeneron Pharmaceuticals, Inc. | 13.11 Billion USD | 65.663% |
| Corbus Pharmaceuticals Holdings, Inc. | - USD | -Infinity% |
| Homology Medicines, Inc. | -6.65 Million USD | 67819.14% |
| Nektar Therapeutics | 90.12 Million USD | -4897.67% |
| TG Therapeutics, Inc. | 233.66 Million USD | -1827.571% |
| Viking Therapeutics, Inc. | - USD | -Infinity% |
| Perrigo Company plc | 4.65 Billion USD | 3.256% |
| Unity Biotechnology, Inc. | - USD | -Infinity% |